Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 52.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 78,494 shares of the biopharmaceutical company's stock after purchasing an

Gilead Sciences, Inc. shares have risen more than 43% over the past year. I continue to believe that its three key drugs remain Biktarvy, Yeztugo, and Livdelzi, whose total sales grew 10.8% year-over-year to $4.2 billion in Q4. On the other hand, sales of Gilead's oncology franchise leave much to be desired, despite its numerous attempts to compete with Merck, Pfizer, and AstraZeneca.

China Universal Asset Management Co. Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 4.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,155 shares of the biopharmaceutical company's stock after buying an

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares of the company's

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CROI2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities affected by HIV, notable late-breaking abstra.

Cookson Peirce and Co. Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 249.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,045 shares of the biopharmaceutical company's stock after acquiring an additional 7,168 shares

Atria Investments Inc trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 75,057 shares of the biopharmaceutical company's stock after selling 3,969 shares during the quarter.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.